| abstract |
the present invention provides a somatostatin receptor subtype 2 agonist. the compound disclosed in this report is represented by the general formula (i): in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof is a low molecular weight compound that has strong agonistic activity for subtype 2 of the somatostatin receptor and can be administered orally. therefore, the present compound can be easily administered and can relieve pain accompanied by patient therapy. the present compound also has sufficiently weak herg inhibitory activity and / or phospholipidosis action in relation to the sstr2 agonistic activity and, thus, can suppress or alleviate the side effects resulting from the activity / action. |